Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGLTS:0SAN +0.60%37 EV-to-EBIT is 42.22 as of Aug. 16, 2026, which is 33% below its 10-year median of 62.84. GuruFocus rates LTS:0SAN with a GF Score™ of 37/100 and a GF Value™ of CHF46.95 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 682 Drug Manufacturers companies, Sandoz Group AG ranks worse than 81.67% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sandoz Group AG's Enterprise Value for the quarter that ended in Jun. 2026 was CHF35,598 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF844 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG EV-to-EBIT Related Terms
Sandoz Group AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0SAN vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's EV-to-EBIT falls into.
Sandoz Group AG's current Enterprise Value is CHF35,620 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF844 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (LTS:0SAN) has a EV-to-EBIT of 42.22 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sandoz Group AG and its competitors. This is 33% below median its historical median of 62.84. Over the past decade, Sandoz Group AG's EV-to-EBIT has ranged from 9.65 to 134.15. According to the industry distribution chart, Sandoz Group AG ranks #557 out of 682 companies in the Drug Manufacturers industry, placing it in the top 81.7%.
Is Sandoz Group AG's EV-to-EBIT too high?
Sandoz Group AG's current EV-to-EBIT of 42.22 is 33% below median its 10-year median of 62.84. Over the past 10 years, this metric has ranged from a low of 9.65 to a high of 134.15. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Sandoz Group AG's value of 42.22 is 166.3% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #557 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sandoz Group AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #557 out of 682 companies for EV-to-EBIT. This places Sandoz Group AG in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Sandoz Group AG's value of 42.22 is 166.3% above this benchmark. Historically, Sandoz Group AG's own EV-to-EBIT has ranged from 9.65 to 134.15 over the past decade. While the company's 10-year median is 62.84 vs. the industry median of 15.86, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current EV-to-EBIT of 42.22 is 166.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current EV-to-EBIT is 42.22, which is 33% below median its own 10-year median of 62.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (LTS:0SAN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF46.95, compared to a current price of CHF73.30 — trading 56.1% above its estimated fair value. The current EV-to-EBIT is 42.22, which is 33% below median its 10-year median of 62.84 and 166.3% above the Drug Manufacturers industry median of 15.86. Sandoz Group AG's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sandoz Group AG (LTS:0SAN), the current EV-to-EBIT is 42.22 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (LTS:0SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of CHF73.30 is trading 56.1% above its estimated GF Value™ of CHF46.95.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for LTS:0SAN:
EV-to-EBIT: 42.22 (33% below median its 10-year median of 62.84)
GF Value™: CHF46.95 vs. price of CHF73.30 (56.1% above fair value)
Industry Position: 166.3% above the Drug Manufacturers median (#557 of 682)
No single metric tells the full story. See the LTS:0SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
37GF Score
Get the complete analysis for LTS:0SAN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0SAN has been successfully added to your 
